AlDeghaither Dalal, Smaglo Brandon G, Weiner Louis M
Georgetown Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
J Clin Pharmacol. 2015 Mar;55 Suppl 3(0 3):S4-20. doi: 10.1002/jcph.407.
Biotherapeutics are attractive anti-cancer agents due to their high specificity and limited toxicity compared to conventional small molecules. Antibodies are widely used in cancer therapy, either directly or conjugated to a cytotoxic payload. Peptide therapies, though not as prevalent, have been utilized in hormonal therapy and imaging. The limitations associated with unmodified forms of both types of biotherapeutics have led to the design and development of novel structures, which incorporate key features and structures that have improved the molecules' abilities to bind to tumor targets, avoid degradation, and exhibit favorable pharmacokinetics. In this review, we highlight the current status of monoclonal antibodies and peptides, and provide a perspective on the future of biotherapeutics using novel constructs.
生物疗法作为抗癌药物颇具吸引力，因为与传统小分子药物相比，它们具有高特异性和低毒性。抗体在癌症治疗中被广泛应用，可直接使用或与细胞毒性载荷结合。肽疗法虽然不如抗体疗法普遍，但已用于激素治疗和成像。这两种生物疗法的未修饰形式所存在的局限性促使了新型结构的设计与开发，这些新型结构融入了关键特征和结构，提高了分子与肿瘤靶点结合、避免降解以及展现良好药代动力学的能力。在本综述中，我们重点介绍单克隆抗体和肽的现状，并对使用新型构建体的生物疗法的未来发展提供展望。
